Neurotherapeutics Presents Special Issue on New Treatments for Alzheimer's Disease
State-of-the-Art Update to Be Available at ICAD 2008 in Chicago
Chicago, 24 July 2008 –The editors of Neurotherapeutics are pleased and proud to announce their July issue, devoted to "Novel Therapeutics for Alzheimer's Disease." Neurotherapeutics is the journal of the American Society of Experimental NeuroTherapeutics (ASENT).
The issue coincides with the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), being held at McCormick Place, Chicago, July 26 to 31, 2008. Rudolph E. Tanzi, Ph.D., of the Massachusetts General Institute for Neurodegenerative Disease and Massachusetts General Hospital, is a Guest Editor. "In this issue of Neurotherapeutics, we have enlisted several experts in the field to review the most promising new therapeutics currently under development for the treatment and prevention of AD," Dr. Tanzi writes in the introductory editorial.
The eleven papers in the special issue highlight promising therapeutic targets for Alzheimer's disease, providing an update on efforts to develop treatments. Given the central role of amyloid β peptide (Aβ) in the pathogenesis of Alzheimer's disease, cerebral accumulations of Aβ are a major focus. The lead article in the issue looks at techniques for measuring the effects of disease-modifying therapies on cerebral Aβ levels—including the key question of whether they correlate with cognitive performance.
Clinical trials aimed at all of these therapeutic targets are underway. In his editorial, Dr. Tanzi expresses "cautious optimism and high hopes" that these trials may lead to new therapeutic approaches to Alzheimer's disease. He concludes, "With several active clinical trials and other promising drugs now headed toward the clinic, the hope is that we will soon have novel AD therapeutics that successfully slow or reverse disease progress in AD."
The full text of Dr. Bush's and Dr. Tanzi's paper on the metal hypothesis has been made available free of charge at http://www.neurotherapeutics.org/content/editorschoice. As always, subscribers and ASENT members can access the full content of each issue of Neurotherapeutics at the journal website, www.neurotherapeutics.org. Institutional subscribers can access the journal through ScienceDirect.
Visitors to ICAD 2008 in Chicago are encouraged to stop by the Elsevier display in the Expo Hall (Booth #710) to see the special issue on "Novel Therapeutics for Alzheimer's Disease" and to learn about options for becoming a Neurotherapeutics subscriber.
# # #
Neurotherapeutics, the official publication of the American Society of Experimental NeuroTherapeutics (ASENT), provides original articles and critical reviews focused on an important topic relating to the treatment of disorders of the nervous system, written by international authorities. The Editor-in-Chief is Alan I. Faden, M.D. More information about the journal can be found online at www.neurotherapeutics.org.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+1 215 239 3653